

# Emma Jane Dean

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2373550/publications.pdf>

Version: 2024-02-01

31  
papers

1,378  
citations

361413

20  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2847  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	3.0	29
2	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019, 25, 738-743.	30.7	202
3	A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 873-883.	2.3	15
4	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	6.4	72
5	Malignant bowel obstruction in advanced ovarian cancer. <i>Future Oncology</i> , 2017, 13, 513-521.	2.4	12
6	Novel Early Phase Clinical Trial Design in Oncology. <i>Pharmaceutical Medicine</i> , 2017, 31, 297-307.	1.9	3
7	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. <i>Targeted Oncology</i> , 2016, 11, 401-415.	3.6	103
8	A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of $\hat{I}\pm 2$ integrin inhibitor E7820 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 329-337.	2.6	22
9	Selumetinib in the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 2545-2560.	2.4	23
10	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. <i>Advances in Therapy</i> , 2015, 32, 510-522.	2.9	39
11	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	7.0	101
12	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6284-6294.	7.0	24
13	Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. <i>British Journal of Cancer</i> , 2013, 108, 1704-1711.	6.4	32
14	Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2012, 106, 468-474.	6.4	122
15	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1437-1448.	2.4	24
16	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1518-1524.	6.4	33
17	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 432-441.	2.6	19
18	Biomarkers of cell death applicable to early clinical trials. <i>Experimental Cell Research</i> , 2012, 318, 1252-1259.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Optimization of Circulating Biomarkers of Obatoclox-Induced Cell Death in Patients with Small Cell Lung Cancer. <i>Neoplasia</i> , 2011, 13, 339-347.	5.3	19
20	A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®; OSI-774) in patients with advanced solid tumors of epithelial origin. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 53-58.	2.3	29
21	A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. <i>British Journal of Cancer</i> , 2010, 102, 97-103.	6.4	34
22	Targeted Therapies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2010, 2, 88-113.	3.7	12
23	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. <i>Annals of Oncology</i> , 2010, 21, 2233-2239.	1.2	35
24	Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1660-1666.	1.6	88
25	Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. <i>Cancer Biomarkers</i> , 2009, 5, 117-125.	1.7	13
26	Biomarkers of apoptosis. <i>British Journal of Cancer</i> , 2008, 99, 841-846.	6.4	101
27	X-linked inhibitor of apoptosis protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1459-1471.	3.4	44
28	IAPs as a Target for Anticancer Therapy. <i>Current Cancer Drug Targets</i> , 2007, 7, 785-794.	1.6	66
29	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. <i>Cancer Treatment Reviews</i> , 2007, 33, 203-212.	7.7	44
30	Catastrophic lower gastrointestinal complications following spinal surgery. <i>Gut</i> , 2006, 55, 1262-1262.	12.1	1
31	Second-line treatment of postmenopausal women with advanced breast carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 613-624.	2.4	0